CD8A and cancer: To examine whether avelumab similarly enhances the development of antigen-specific responses in cancer patients, PBMCs from patients with metastatic breast cancer (n=7) were stimulated with CEFT or HLA peptide pools in the presence or absence of avelumab, and were assessed for the development of antigen-specific responses in CD8+ T cells.